These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 33795385)

  • 21. The validity of progression-free survival 2 as a surrogate trial end point for overall survival.
    Woodford RG; Zhou DD; Kok PS; Lord SJ; Friedlander M; Marschner IC; Simes RJ; Lee CK
    Cancer; 2022 Apr; 128(7):1449-1457. PubMed ID: 34985773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy-Based Combinations in First-Line Urothelial Cancer: A Systematic Review and Individual Patient Data (IPD) Meta-Analysis.
    Di Civita MA; Torchia A; Santini D; Marinelli D; Magro V; Cerro M; Pappalardo L; Maltese G; Santamaria F; Zacco L; Buccilli D; Dehghanpour A; Speranza I; Sciarra A; Panebianco V; Roberto M
    Curr Oncol; 2024 Aug; 31(8):4713-4727. PubMed ID: 39195335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolution of randomized controlled trials and surrogacy of progression-free survival in advanced/metastatic urothelial cancer.
    Liang F; Zhang S; Wang Q; Li W
    Crit Rev Oncol Hematol; 2018 Oct; 130():36-43. PubMed ID: 30196910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between progression-free survival and overall survival in patients with advanced non-small cell lung cancer treated with anticancer agents after first-line treatment failure.
    Suzuki H; Hirashima T; Okamoto N; Yamadori T; Tamiya M; Morishita N; Shiroyama T; Takeoka S; Osa A; Azuma Y; Kawase I
    Asia Pac J Clin Oncol; 2015 Jun; 11(2):121-8. PubMed ID: 24811212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.
    Michiels S; Saad ED; Buyse M
    Drugs; 2017 May; 77(7):713-719. PubMed ID: 28337673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predict progression free survival and overall survival using objective response rate for anti-PD1/PDL1 therapy development.
    Yang L; Raveendran G; Meng X; Lin J; Meng Z
    BMC Cancer; 2024 Jul; 24(1):912. PubMed ID: 39075397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The landscape of checkpoint inhibitors in oncology.
    Haslam A; Kim MS; Elbaz J; Prasad V
    Eur J Cancer; 2024 Sep; 209():114240. PubMed ID: 39084136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of antibiotics on efficacy of immune checkpoint inhibitors in malignancies: A study based on 44 cohorts.
    Wu Q; Liu J; Wu S; Xie X
    Int Immunopharmacol; 2021 Mar; 92():107303. PubMed ID: 33465728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings.
    Hua T; Gao Y; Zhang R; Wei Y; Chen F
    BMC Cancer; 2022 Sep; 22(1):1022. PubMed ID: 36171546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors.
    Zhou J; Huang G; Wong WC; Hu DH; Zhu JW; Li R; Zhou H
    Front Immunol; 2022; 13():968729. PubMed ID: 35967438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis.
    Kaufman HL; Schwartz LH; William WN; Sznol M; Fahrbach K; Xu Y; Masson E; Vergara-Silva A
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2245-2261. PubMed ID: 30132118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
    Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N
    Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis.
    Liu C; Guo H; Mao H; Tong J; Yang M; Yan X
    Front Oncol; 2022; 12():753234. PubMed ID: 35280736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
    Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibiotic administration shortly before or after immunotherapy initiation is correlated with poor prognosis in solid cancer patients: An up-to-date systematic review and meta-analysis.
    Yang M; Wang Y; Yuan M; Tao M; Kong C; Li H; Tong J; Zhu H; Yan X
    Int Immunopharmacol; 2020 Nov; 88():106876. PubMed ID: 32799113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
    Wang X; Wang X; Hodgson L; George SL; Sargent DJ; Foster NR; Ganti AK; Stinchcombe TE; Crawford J; Kratzke R; Adjei AA; Kindler HL; Vokes EE; Pang H
    Oncologist; 2017 Feb; 22(2):189-198. PubMed ID: 28188257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
    Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
    JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive evaluation of surrogate endpoints to predict overall survival in trials with PD1/PD-L1 immune checkpoint inhibitors plus chemotherapy.
    Villacampa G; Cresta Morgado P; Navarro V; Viaplana C; Dienstmann R
    Cancer Treat Rev; 2023 May; 116():102542. PubMed ID: 37003083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Maiorano BA; Di Maio M; Cerbone L; Maiello E; Procopio G; Roviello G;
    JAMA Netw Open; 2024 Mar; 7(3):e241215. PubMed ID: 38446479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.